Myeloproliferative Disorders
"Myeloproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Descriptor ID |
D009196
|
| MeSH Number(s) |
C15.378.190.636
|
| Concept/Terms |
Myeloproliferative Disorders- Myeloproliferative Disorders
- Disorder, Myeloproliferative
- Disorders, Myeloproliferative
- Myeloproliferative Disorder
|
Below are MeSH descriptors whose meaning is more general than "Myeloproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Myeloproliferative Disorders".
This graph shows the total number of publications written about "Myeloproliferative Disorders" by people in this website by year, and whether "Myeloproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 1 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 7 | 0 | 7 |
| 2008 | 3 | 1 | 4 |
| 2009 | 4 | 0 | 4 |
| 2010 | 4 | 0 | 4 |
| 2011 | 4 | 0 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 5 | 1 | 6 |
| 2015 | 3 | 1 | 4 |
| 2016 | 4 | 0 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 4 | 0 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 1 | 5 |
| 2022 | 6 | 0 | 6 |
| 2023 | 3 | 0 | 3 |
| 2024 | 3 | 3 | 6 |
| 2025 | 3 | 0 | 3 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloproliferative Disorders" by people in Profiles.
-
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee. Bone Marrow Transplant. 2026 May; 61(5):591-600.
-
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes. Leukemia. 2026 May; 40(5):946-954.
-
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Adv. 2025 Nov 11; 9(21):5598-5609.
-
Loss of Socs2 improves molecular responses to IFNa in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025 Apr; 39(4):876-887.
-
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025 02 06; 145(6):612-624.
-
Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms. J Clin Oncol. 2024 Nov; 42(31):3739-3750.
-
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
-
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.
-
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol. 2024 07; 99(7):1434-1436.
-
IL-1? promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024 03 12; 8(5):1234-1249.